Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаи Сейяку Кабусики КайсяfiledCriticalЧугаи Сейяку Кабусики Кайся
Publication of RU99127290ApublicationCriticalpatent/RU99127290A/en
Application grantedgrantedCritical
Publication of RU2227748C2publicationCriticalpatent/RU2227748C2/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to a therapeutic agent for treatment of cachexia that comprises a substance as an active component able to inhibit binding protein related to human parathyroid hormone (PTHrP) with its receptor. Invention provides prevention of weight loss and to increase survival time of myeloma-bearing experimental animals. EFFECT: valuable medicinal properties of agent. 5 cl, 19 dwg, 2 tbl
Description
Текст описания в факсимильном виде (см. графическую часть).Description text in facsimile form (see graphic part).
Claims (5)
1. Применение антитела против РТНrР для получения лекарственного средства для профилактики или лечения кахексии, вызванной раком.1. The use of antibodies against PTH-P to obtain drugs for the prevention or treatment of cachexia caused by cancer.2. Применение по п.1, отличающееся тем, что вещество характеризуется (а) активностью в отношении профилактики или лечения кахексии и (b) отсутствием существенной активности в отношении ингибирования роста опухолевых клеток ОСС-1.2. The use according to claim 1, characterized in that the substance is characterized by (a) activity against the prevention or treatment of cachexia and (b) the absence of significant activity against growth inhibition of tumor cells OSS-1.3. Применение по п.1, отличающееся тем, что антителом является гуманизированное или химерное антитело.3. The use according to claim 1, characterized in that the antibody is a humanized or chimeric antibody.4. Применение по п.3, отличающееся тем, что гуманизированное антитело является гуманизированным антителом №23-57-137-1.4. The use according to claim 3, characterized in that the humanized antibody is a humanized antibody No. 23-57-137-1.5. Применение по п.1, отличающееся тем, что антитело относится к моноклональному типу.5. The use according to claim 1, characterized in that the antibody belongs to the monoclonal type.
RU99127290/15A1997-05-151998-05-13Therapeutic agent for treatment of cachexia
RU2227748C2
(en)
Chimeric antibody that binds with human cd40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treatment of disease mediated by t-cells (variants), method for treatment of patient with diseases mediated by t-cells (variants)
Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
